Online inquiry

IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1393MR)

This product GTTS-WQ1393MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL1A&IL1B gene. The antibody can be applied in Osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000575.5; NM_000576.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3552; 3553
UniProt ID P01583; P01584
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ1393MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5650MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDP870
GTTS-WQ13727MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA RC48-0
GTTS-WQ4095MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BI-204
GTTS-WQ784MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Ab-2
GTTS-WQ15110MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SYD985
GTTS-WQ3615MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ7587MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA G-CSF
GTTS-WQ7146MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FG-3019
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW